The first artificial intelligence lung cancer-assisted diagnostic system was approved for sale

according to the 2019 National Cancer Report released by the National Cancer Center, the number of lung cancer cases in China reached 784,000 in 2019, with morbidity and mortality accounting for 20.03 percent and 26.99 percent of all malignant tumors, respectively. In recent years, a number of anti-PD-1/PD-L1 inhibitors have appeared in the field of immunotherapy at home and abroad, and with the emergence of innovative treatment methods such as immunotherapy, the long-term survival rate and quality of life of lung cancer patients have been effectively improved.
cell programmed death subject-litherapy 1 (PD-L1) protein expression level is an important marker of advanced non-small cell lung cancer immunotherapy, through PD-L1 testing can be screened the most suitable tumor immunotherapy benefit groups. London-based AstraZenecom announced that its artificial intelligence-assisted non-small cell lung cancer PD-L1, developed in collaboration with China's Hangzhou Diyinga Technology Co., Ltd., has been awarded a Class II medical device registration certificate by the Zhejiang Provincial Drug Administration, becoming the first artificial intelligence lung cancer-assisted diagnostic system in China to be approved for clinical applications.
2019, released by the Chinese Academy of Engineering, intelligent assisted diagnostics is listed as one of the cutting-edge technologies in emerging development. Intelligent auxiliary diagnosis refers to the computer in clinical diagnosis to provide auxiliary disease analysis, to help doctors make full use of multi-ion information to improve the quality of diagnosis and treatment efficiency. One of the hot directions of the development of intelligent assisted diagnostic technology is the intelligent analysis of imaging histology, that is, the use of artificial intelligence technology to process CT, pathology and other full modal image data in all directions.
latest survey data show that by the end of 2018, china's registered pathologists about 18,000 people, according to the standard of 1 to 2 pathologists per 100 beds, China's pathologist gap of about 90,000 people. In addition, china's pathologist resources at all levels of hospitals, especially primary hospitals are unevenly distributed, pathology as a basic discipline, its diagnosis will directly affect the diagnosis and treatment level of various diseases, including tumors. In the traditional mode, pathologists make disease diagnosis by observing cell and tissue lesions on pathological slices through a microscope, and manual reading takes time and labor, is inefficient, and it is difficult to identify difficult tumor cells quickly and accurately.
"Immune grouped digital pathology image processing software" by the domestic authoritative pathologist data labeling, algorithm model effectively solves the cell membrane damage caused by the location is not allowed and other technical problems, through artificial intelligence to assist pathologists for non-small cell lung cancer PD-L1 reading, integrated analysis, unattended can obtain the full analysis results. Doctors only need to review can quickly and accurately complete the PD-L1 full-piece reading, effectively save human and time costs, improve the pathological diagnosis quality and efficiency of non-small cell lung cancer, primary hospitals can also be difficult PD-L1 tissue slices through remote consultation mode directly sent to large city center hospitals, by breaking the space-time geographical limit of "cloud pathology" and further improve the level of tumor pathology diagnosis.